Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRONTIER 4 long-term safety and efficacy study of Mim8 in haemophilia A
2022-502215-10-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Apr 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, open-label trial of denecimig in hemophilia A (2 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treatment-emergent adverse events. Planned start Apr 2023; status: authorised.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2022-502215-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502215-10-00.